{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:09:17Z","timestamp":1720609757364},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1157\/13126267","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T18:15:16Z","timestamp":1227377716000},"page":"13-18","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S8","title":["Datos cl\u00ednicos II. Experiencia cl\u00ednica de tenofovir en combinaciones con inhibidores de proteasa"],"prefix":"10.1016","volume":"26","author":[{"given":"Federico","family":"Pulido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Fiorante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13126267_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0166-3542(97)00043-0","article-title":"Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses","volume":"36","author":"Mulato","year":"1997","journal-title":"Antiviral Res"},{"key":"10.1157\/13126267_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2893.2000.00192.x","article-title":"Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture","volume":"7","author":"Ying","year":"2000","journal-title":"J Viral Hepat"},{"key":"10.1157\/13126267_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2125.2004.02240.x","article-title":"Pharmacokinetics of saquinavir hard gel\/ritonavir (1000\/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects","volume":"59","author":"Boffito","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13126267_bib4","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/QAD.0b013e32810c8ce2","article-title":"Fosamprenavir\/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir","volume":"21","author":"Kurowski","year":"2007","journal-title":"Aids"},{"key":"10.1157\/13126267_bib5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/QAD.0b013e328133f068","article-title":"Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects","volume":"21","author":"Parks","year":"2007","journal-title":"Aids"},{"key":"10.1157\/13126267_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","article-title":"Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir\/Ritonavir","volume":"43","author":"Kearney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126267_bib7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2125.2007.02957.x","article-title":"Pharmacokinetic interaction between TMC114\/ritonavir and tenofovir disoproxil fumarate in healthy volunteers","volume":"64","author":"Hoetelmans","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13126267_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00228-006-0122-2","article-title":"Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients","volume":"62","author":"Dailly","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13126267_bib9","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.48.6.2091-2096.2004","article-title":"Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients","volume":"48","author":"Taburet","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13126267_bib10","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00671-07","article-title":"Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro","volume":"51","author":"Tong","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13126267_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.clpt.6100269","article-title":"The effect of lopinavir\/ritonavir on the renal clearance of tenofovir in HIV-infected patients","volume":"83","author":"Kiser","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13126267_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135965350701200211","article-title":"Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors","volume":"12","author":"Cihlar","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1157\/13126267_bib13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"2-3","key":"10.1157\/13126267_bib14","article-title":"Tenofovir: Gilead applies for approval; expanded access liberalized","volume":"364","author":"Gilden","year":"2001","journal-title":"AIDS Treat News"},{"key":"10.1157\/13126267_bib15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.46.4.1067-1072.2002","article-title":"Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates","volume":"46","author":"Harrigan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13126267_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-na\u00efve patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13126267_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13126267_bib18","series-title":"13th Conference on Retroviruses and Opportunistic Infections","article-title":"Didanosine and lower baseline body weight are associated with declining renal function among patients receiving tenofovir","author":"Crane","year":"2006"},{"key":"10.1157\/13126267_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.aids.0000216371.76689.63","article-title":"96-week comparison of once-daily atazanavir\/ritonavir and twice-daily lopinavir\/ritonavir in patients with multiple virologic failures","volume":"20","author":"Johnson","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13126267_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.qai.0000242449.67155.1a","article-title":"A once-daily lopinavir\/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen","volume":"43","author":"Johnson","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126267_bib21","series-title":"15th Conference on Retrovirus and Opportunistic Infection","author":"Gathe","year":"2008"},{"key":"10.1157\/13126267_bib22","series-title":"15th Conference on Retrovirus and Opportunistic Infection","article-title":"Efficacy and safety of one-daily atazanavir\/ritonavir compared to twice- daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabinein ARV-na\u00efve HIV- 1 infected subjets: The CASTLE Study, 48-week Results","author":"Molina","year":"2008"},{"key":"10.1157\/13126267_bib23","series-title":"11th European AIDS Conference, Madrid","article-title":"Saquinavir\/r (SQV\/r) BiD versus lopinavir\/r (LPV\/r) BiD, plus emtricitabine\/tenofovir (FTC\/TDF) QD as initial therapy in HIV-1 infected patients: the GEMINI study","author":"Walmsley","year":"2007"},{"key":"10.1157\/13126267_bib24","series-title":"Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Efficacy and safety of darunavir\/ritonavir versus lopinavir\/ritonavir in ARV treatment-na\u00efve HIV-1 infected patients at week 48: ARTEMIS (TMC114-C 211)","author":"DeJes\u00fas","year":"2007"},{"key":"10.1157\/13126267_bib25","series-title":"15th Conference on Retrovirus and Opportunistic Infection","article-title":"Efficacy and safety of abacavir\/lamivudine compared to tenofovir\/emtricitabine in combination with once daily lopinavir \/ritonavir through 48 weeks in the HEAT Study","author":"Smith","year":"2008"},{"key":"10.1157\/13126267_bib26","series-title":"3rd Intenational Workshop on HIV and Hepatitis Coinfection","article-title":"Effectiveness and safety of HAART regimens containing tenofovir DF + protease inhibitors in HIV\/HVC co-Infected vs non-coinfected patients. Subanalysis from the Protection Spanish Cohort","author":"Collado","year":"2007"},{"key":"10.1157\/13126267_bib27","series-title":"9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Sydney, Australia","article-title":"Evolution of the lipid profile changes in patients treated with tenofovir DF and protease inhibitors. Data from the PROTECTION Cohort Study","author":"Llibre","year":"2007"},{"key":"10.1157\/13126267_bib28","series-title":"9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV","article-title":"Renal safety profile of TDF in combination with protease inhibitors (PI) in a clinical setting. Results from the PROTECTION Cohort","author":"Viciana","year":"2007"},{"key":"10.1157\/13126267_bib29","series-title":"X Congreso de la Sociedad Andaluza de Enfermedades Infecciosas","article-title":"Efectividad y seguridad de tenofovir DF y abacavir en combinaci\u00f3n con inhibidores de la proteasa. Resultados de la cohorte PROTECTION","author":"M\u00e1rquez","year":"2007"},{"key":"10.1157\/13126267_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"197","author":"Goicoechea","year":"2008","journal-title":"J Infect Dis"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08765261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08765261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T08:11:54Z","timestamp":1684656714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X08765261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":30,"alternative-id":["S0213005X08765261"],"URL":"https:\/\/doi.org\/10.1157\/13126267","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}